Analytical Data
-
Gene name
Inhibin beta C chain/INHBC
- Application
-
Alternative Names
Inhibin Beta C Chain; Activin Beta-C Chain; INHBC
-
Species
Human
-
Source
HEK293
-
Tag
C- His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P55103
-
Expression Region
19-352aa
-
Protein Length
Partial
-
Molecular Weight
37.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Inhibin beta C chain (INHBC) is a member of the inhibin family of hormones, which are important regulators of reproductive processes and follicle development. INHBC primarily functions in the female reproductive system, where it plays a crucial role in modulating follicle-stimulating hormone (FSH) activity and inhibiting excessive ovarian stimulation. Research has highlighted the potential of INHBC as a biomarker for various reproductive disorders and ovarian function, as its expression levels can change significantly in conditions such as polycystic ovary syndrome (PCOS) and ovarian cancer. The recombinant production of INHBC protein enables detailed studies on its biological functions, interactions with other hormones, and potential therapeutic applications. Furthermore, understanding the role of INHBC in the endocrine system could pave the way for novel treatments targeting fertility issues. Advances in recombinant DNA technology have made it possible to produce high-purity INHBC for experimental purposes, facilitating research into its physiological relevance and enhancing knowledge concerning reproductive health. Overall, the study of recombinant INHBC not only contributes to basic scientific understanding but also holds promise for clinical applications in reproductive medicine.
